Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials units
Open Access
- 27 June 2022
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-11
Abstract
Background: Blinding is an established approach in clinical trials which aims to minimise the risk of performance and detection bias. There is little empirical evidence to guide UK clinical trials units (CTUs) about the practice of blinding statisticians. Guidelines recommend that statisticians remain blinded to allocation prior to the final analysis. As these guidelines are not based on empirical evidence, this study undertook a qualitative investigation relating to when and how statisticians should be blinded in clinical trials. Methods: Data were collected through online focus groups with various stakeholders who work in the delivery and oversight of clinical trials. Recordings of the focus groups were transcribed verbatim and thematic analysis was used to analyse the transcripts. Results: Thirty-seven participants from 19 CTUs participated in one of six focus groups. Four main themes were identified, namely statistical models of work, factors affecting the decision to blind statisticians, benefits of blinding/not blinding statisticians and practicalities. Factors influencing the decision to blind the statistician included available resources, study design and types of intervention and outcomes and analysis. Although blinding of the statistician is perceived as a desirable mitigation against bias, there was uncertainty about the extent to which an unblinded statistician might impart bias. Instead, in most cases, the insight that the statistician offers was deemed more important to delivery of a trial than the risk of bias they may introduce if unblinded. Blinding of statisticians was only considered achievable with the appropriate resource and staffing, which were not always available. In many cases, a standard approach to blinding was therefore considered unrealistic and impractical; hence the need for a proportionate risk assessment approach identifying possible mitigations. Conclusions: There was wide variation in practice between UK CTUs regarding the blinding of trial statisticians. A risk assessment approach would enable CTUs to identify risks associated with unblinded statisticians conducting the final analysis and alternative mitigation strategies. The findings of this study will be used to design guidance and a tool to support this risk assessment process.Keywords
This publication has 22 references indexed in Scilit:
- Blinding in pharmacological trials: the devil is in the detailsArchives of Disease in Childhood, 2013
- Recruitment, Retention, and Blinding in Clinical TrialsAmerican Journal of Occupational Therapy, 2013
- Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessorsCanadian Medical Association Journal, 2013
- Practical tips for surgical research: blinding: who, what, when, why, how?2010
- Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groupsInternational Journal for Quality in Health Care, 2007
- Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authorsClinical Trials, 2006
- Issues in data monitoring and interim analysis of trialsHealth Technology Assessment, 2005
- What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?Statistics in Medicine, 2004
- Monitoring clinical trials: issues and controversies regarding confidentialityStatistics in Medicine, 2002
- Correlation of Quality Measures With Estimates of Treatment Effect in Meta-analyses of Randomized Controlled TrialsJAMA, 2002